Related Experiment Video
Updated: Mar 21, 2026

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
Thrombolytic therapy before percutaneous coronary intervention improves short-term cardiac function evaluated by
Jiani Yin1,2, Hao Gong1, Yunfei Wang1
1Department of Radiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, PR China.
Insights
Half-dose recombinant staphylokinase (r-SAK) before percutaneous coronary intervention (PCI) in ST-segment elevation myocardial infarction (STEMI) patients improved cardiac function and strain without increasing adverse events.
Area of Science:
- Cardiology
- Interventional Cardiology
- Biomedical Imaging
Background:
- Thrombolytic therapy before percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI) is debated.
- Further research is needed to assess the benefits of pre-PCI thrombolysis.
Purpose of the Study:
- To evaluate the efficacy of a half-dose recombinant staphylokinase (r-SAK) intravenous bolus administered before PCI in STEMI patients.
Main Methods:
- STEMI patients were randomized to receive either r-SAK or normal saline before PCI.
- Cardiac magnetic resonance (CMR) assessed cardiac function, myocardial characteristics, and strain at 5 days post-MI.
- Segments were categorized by late gadolinium enhancement (LGE) extent.
Main Results:
- The r-SAK group (n=33) showed improved left ventricular ejection fraction and cardiac output index compared to the normal saline group (n=31).
- No significant differences were observed in infarct size, area at risk, microvascular obstruction (MVO), or intramyocardial hemorrhage (IMH).
- Patients receiving r-SAK demonstrated significantly better segmental longitudinal strain and improved segmental circumferential strain in LGE segments.
Conclusions:
- A single half-dose r-SAK bolus before PCI in STEMI patients improved short-term cardiac function and strain.
- This approach did not increase the incidence of MVO or IMH, suggesting a favorable safety profile.
Abstract:
BackgroundThe necessity of thrombolytic therapy before percutaneous coronary intervention (PCI) in ST-segment elevation myocardial infarction (STEMI) patients remains controversial, requiring further evaluation of potential benefits.PurposeTo explore the efficacy of half-dose recombinant staphylokinase (r-SAK) intravenous bolus before PCI in STEMI patients.Material and MethodsPatients with STEMI were allocated to r-SAK or normal saline groups before PCI. Cardiac magnetic resonance (CMR) at 5 days after MI evaluated cardiac function, myocardial tissue characteristics, and strain. Segments were classified by late gadolinium enhancement (LGE) extent.ResultsA total of 64 STEMI patients were divided into the r-SAK group (n = 33) and NS group (n = 31). Patients in the r-SAK group had a significantly higher left ventricular ejection fraction and cardiac output index (P = 0.045 and 0.024). There was no significant difference between the two groups in mapping parameters, infarct size, area at risk, or the incidence of microvascular obstruction (MVO) and intramyocardial hemorrhage (IMH) (all P >0.05). Regardless of the extent of LGE in the segments, patients in the r-SAK group exhibited significantly better segmental longitudinal strain (all P <0.001). In addition, patients from the r-SAK group had a better segmental circumferential strain in LGE segments (P = 0.044).ConclusionFor STEMI patients expected to undergo PCI within 120 min of presentation, a single bolus of half-dose r-SAK administrated before PCI improved short-term cardiac function without increasing incidence of MVO or IMH.
Related Concept Videos
Acute Coronary Syndrome IV: Interprofessional Care
Acute Coronary Syndrome I: Introduction
Coronary Artery Disease V: Interprofessional Care
Acute Coronary Syndrome III: Diagnostic Studies
Venous Thrombosis III: Interprofessional Care
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

